{"id":"msi-78","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Pain at application site"},{"rate":null,"effect":"Erythema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MSI-78 is a synthetic antimicrobial peptide derived from magainin that works by inserting into and destabilizing bacterial cell membranes, leading to cell lysis and death. It is designed to be effective against multidrug-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa and other difficult-to-treat pathogens. The peptide-based mechanism offers a novel approach distinct from traditional antibiotics.","oneSentence":"MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:17.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic foot ulcers with Pseudomonas aeruginosa infection"},{"name":"Multidrug-resistant gram-negative bacterial infections"}]},"trialDetails":[{"nctId":"NCT00563433","phase":"PHASE3","title":"MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers","status":"COMPLETED","sponsor":"Abeona Therapeutics, Inc","startDate":"1994-08","conditions":"Diabetic Foot Ulcers","enrollment":342},{"nctId":"NCT00563394","phase":"PHASE3","title":"MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers","status":"COMPLETED","sponsor":"Abeona Therapeutics, Inc","startDate":"1994-08","conditions":"Diabetic Foot Ulcers","enrollment":584},{"nctId":"NCT01590758","phase":"PHASE3","title":"Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Dipexium Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Diabetic Foot Infection","enrollment":189},{"nctId":"NCT01594762","phase":"PHASE3","title":"Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Dipexium Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Diabetic Foot Infection","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MSI-78","genericName":"MSI-78","companyName":"Abeona Therapeutics, Inc","companyId":"abeona-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens. Used for Diabetic foot ulcers with Pseudomonas aeruginosa infection, Multidrug-resistant gram-negative bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}